Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17053372 | 0.92 | PIK3CD (0.67) | PIK3CDPIK3CA | |
| SCHEMBL20725675 | 0.89 | PIK3CD (0.66) | PIK3CDPIK3CA | |
| SCHEMBL16639064 | 0.89 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL16639101 | 0.87 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL16639062 | 0.86 | PIK3CD (0.60) | PIK3CDPIK3CA | |
| SCHEMBL16639066 | 0.86 | PIK3CD (1.00) | PIK3CDPIK3CA | |
| SCHEMBL16639063 | 0.85 | PIK3CD (0.79) | PIK3CDPIK3CA | |
| SCHEMBL17053366 | 0.85 | PIK3CD (0.58) | PIK3CDPIK3CA | |
| SCHEMBL16639075 | 0.83 | PIK3CD (0.75) | PIK3CDPIK3CA | |
| SCHEMBL16639128 | 0.82 | PIK3CD (0.73) | PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2860181-B1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| EP-2860181-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | Shanghai Yingli Science and Technology Co., Ltd (CN) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.